Skip to main content Accessibility help
×
Hostname: page-component-78c5997874-lj6df Total loading time: 0 Render date: 2024-11-08T08:24:00.183Z Has data issue: false hasContentIssue false

Debate 18B - What is the best front-line maintenance therapy for optimally debulked HRD-negative advanced epithelial ovarian cancer?

PARP Inhibitor

from Section III - Ovarian Cancer

Published online by Cambridge University Press:  20 July 2023

Dennis S. Chi
Affiliation:
Memorial Sloan-Kettering Cancer Center, New York
Nisha Lakhi
Affiliation:
Richmond University Medical Center, Staten Island
Nicoletta Colombo
Affiliation:
University of Milan-Bicocca
Get access

Summary

The integrated genomic analysis of high-grade serous ovarian cancer carried out by The Cancer Genome Atlas Research Network (TCGA) identified two large subgroups of patients, those harboring homologous recombination (HR) deficiency (50%), characterized by genetic and epigenetic alterations of HR genes, most commonly the BRCA1 and BRCA2 genes, and those with an intact HR pathway, enriched in Cyclin E1 (CCNE1) amplifications. These HR-proficient tumors are associated with inferior survival outcomes and poorer response to PARP inhibitors (PARPi), in comparison with HR-deficient tumors [1,2].

Currently, two of the most used commercially available assays to test HR-deficiency status, Myriad myChoice CDx and the Foundation Medicine’s FoundationFocus CDx, are challenged by the reliable identification of HR-proficient tumors.

Type
Chapter
Information
Publisher: Cambridge University Press
Print publication year: 2023

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Ray-Coquard, I, et al. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N Engl J Med 2019;381(25):24162428.CrossRefGoogle ScholarPubMed
González-Martín, A, et al. Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med 2019;381(25):23912402.CrossRefGoogle ScholarPubMed
Mirza, MR, et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med 2016;375(22):21542164.CrossRefGoogle ScholarPubMed
Ledermann, JA, et al. Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial. Lancet Oncol 2020;21(5):710722.CrossRefGoogle ScholarPubMed
Burger, RA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 2011 29;365(26):24732483.CrossRefGoogle Scholar
González, Martín A, et al. Exploratory outcome analyses according to stage and/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab for newly diagnosed ovarian cancer. Gynecol Oncol 2019;152(1):5360.CrossRefGoogle Scholar
Aghajanian, C, et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 2012;30(17):20392045.CrossRefGoogle ScholarPubMed
Pujade-Lauraine, E, et al.Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. J Clin Oncol 2014;32(13):13021308.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×